Literature DB >> 8019556

Mutations in PAX3 associated with Waardenburg syndrome type I.

C T Baldwin1, N R Lipsky, C F Hoth, T Cohen, W Mamuya, A Milunsky.   

Abstract

Waardenburg syndrome (WS) types I, II, and III (McKusick #14882, #19351, and #19350) are related autosomal dominant disorders characterized by sensorineural hearing loss, dystopia canthorum, pigmentary disturbances, and other developmental defects. Disease causing PAX3 mutations have been identified in a few families from each of the three disease subtypes, WS-I, WS-II, and WS-III. In others, although the mutations have not been pinpointed, linkage with the PAX3 locus on chromosome 2q35 has been demonstrated. The PAX3 protein is a transcription factor that contains both a paired-domain and a homeodomain DNA binding motif and appears to play a key role during embryogenesis. In this report, we describe two mutations in the human PAX3 gene that cause WS type I. One mutation is a deletion/frameshift in the paired-domain of PAX3 and results in a protein without functional DNA binding domains. The second mutation is a single-base substitution and results in a premature termination codon in the homeodomain of PAX3. This is the first demonstration of a mutation in the homeodomain DNA binding motif in this protein resulting in WS and one of the few examples of a mutation in a homeodomain of any protein that results in human disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8019556     DOI: 10.1002/humu.1380030306

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  14 in total

Review 1.  Current perspectives on the genetic causes of neural tube defects.

Authors:  Patrizia De Marco; Elisa Merello; Samantha Mascelli; Valeria Capra
Journal:  Neurogenetics       Date:  2006-08-29       Impact factor: 2.660

2.  Targeting the microphthalmia basic helix-loop-helix-leucine zipper transcription factor to a subset of E-box elements in vitro and in vivo.

Authors:  I Aksan; C R Goding
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

3.  Genetic determinants of disease progression in Alzheimer's disease.

Authors:  Xingbin Wang; Oscar L Lopez; Robert A Sweet; James T Becker; Steven T DeKosky; Mahmud M Barmada; F Yesim Demirci; M Ilyas Kamboh
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 4.  The incidence of deafness is non-randomly distributed among families segregating for Waardenburg syndrome type 1 (WS1).

Authors:  R Morell; T B Friedman; J H Asher; L G Robbins
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

5.  Septo-optic dysplasia and WS1 in the proband of a WS1 family segregating for a novel mutation in PAX3 exon 7.

Authors:  M L Carey; T B Friedman; J H Asher; J W Innis
Journal:  J Med Genet       Date:  1998-03       Impact factor: 6.318

6.  Brachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter.

Authors:  S Carreira; T J Dexter; U Yavuzer; D J Easty; C R Goding
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

7.  Locus heterogeneity for Waardenburg syndrome is predictive of clinical subtypes.

Authors:  L A Farrer; K S Arnos; J H Asher; C T Baldwin; S R Diehl; T B Friedman; J Greenberg; K M Grundfast; C Hoth; A K Lalwani
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

8.  Homozygosity for Waardenburg syndrome.

Authors:  J Zlotogora; I Lerer; S Bar-David; Z Ergaz; D Abeliovich
Journal:  Am J Hum Genet       Date:  1995-05       Impact factor: 11.025

9.  Expression of homebox-containing genes in human preimplantation development and in embryos with chromosomal aneuploidies.

Authors:  A Kuliev; V Kukharenko; G Morozov; M Freidine; S Rechitsky; O Verlinsky; V Ivakhnenko; V Gindilis; C Strom; Y Verlinsky
Journal:  J Assist Reprod Genet       Date:  1996-02       Impact factor: 3.412

10.  PAX3 mutations and clinical characteristics in Chinese patients with Waardenburg syndrome type 1.

Authors:  Juan Wang; Shiqiang Li; Xueshan Xiao; Panfeng Wang; Xiangming Guo; Qingjiong Zhang
Journal:  Mol Vis       Date:  2010-06-22       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.